Microtech Achieves First Atrial Microsensor Implantation in the U.S.

Microtech's Landmark Step in Atrial Monitoring

In a remarkable advancement for cardiac medicine, Microtech, a wholly owned subsidiary of Medinol, has successfully completed its first atrial microsensor implantation in the United States. This significant milestone was officially announced following two surgeries conducted on May 16, 2025, at the New York-Presbyterian/Columbia University Irving Medical Center, under the expert guidance of Dr. Koji Takeda, the head of the adult heart transplant department at the facility.

The atrial microsensor developed by Microtech represents an innovative class of devices, noted for their exceptionally small size and fully passive functionality. Distinctively, these microsensors do not incorporate any electronics or antennas, relying instead on ultrasound technology for both signal reception and transmission. This design allows the devices to be deployed as standalone units or to be integrated with existing implants, thereby creating multifunctional therapeutic and diagnostic tools that can gather data and perform various roles concurrently.

The two atrial microsensors implanted on the pioneering date were part of a series of six devices, following successful trials involving five microsensors implanted in Israel under similar conditions. Dr. Takeda reported that the implantation process was streamlined, requiring only about five minutes and necessitating minimal alterations to the existing LVAD (Left Ventricular Assist Device) implantation procedure.

Dr. Nir Uriel, who leads the Advanced Heart Failure and Cardiac Transplantation Division at New York-Presbyterian, highlighted the benefits of such microsensors, stating, "The capability for non-invasive, real-time pressure monitoring of both the left and right atria will markedly enhance our ability to optimize the care of these patients, transitioning from symptomatic treatment to parameter-based therapies." He further emphasized that this technology allows for routine and precise pressure measurements in all participating patients in the ongoing research study.

The First In Human (FIH) study, which includes around 15 patients across both Israel and the United States, aims to explore the full potential of the atrial microsensors developed by Microtech. Dr. Yoram Richter, CEO of Medinol, expressed satisfaction with the study's progress and the functional performance of the microsensors, articulating hopes for continued advancements that will validate the system's efficacy, operational feasibility, and accuracy. Concurrently, the team is focused on integrating the microsensors into current medical devices, thus unlocking the full potential envisioned for this groundbreaking technology.

About Medinol

Medinol is at the forefront of revolutionizing disease diagnosis and treatment paradigms. Whether developing advanced devices for stenting various vascular territories, significantly reducing procedural complexities in Structural Heart interventions, or providing real-time physiological data through implanted sensors, Medinol is committed to redefining current technologies and looking years ahead to create devices that enhance physician capabilities from both a physical and geographical standpoint. In collaboration with healthcare professionals and industry partners, Medinol is shaping the future of medical technology.

For more information about Medinol's innovative medical solutions, visit www.medinol.com or contact Commercial Director, Jeff Roach at [email protected].